Title : Improved anti-psoriatic activity of anti-inflammatory dendrimers using fluid catanionic vesicle-based formulations
Abstract:
Psoriasis is a chronic inflammatory skin disorder that requires effective and well-tolerated anti-inflammatory therapies. A dendrimer-based system with promising immunomodulatory properties has been explored; however, its clinical potential remains limited by insufficient skin penetration, highlighting the need for optimized delivery strategies. In this study, fluid vesicle formulations were developed to enhance cutaneous delivery, and their therapeutic efficacy was evaluated in a murine model of psoriasis, providing new perspectives for topical treatment.
Encapsulation within highly fluid catanionic vesicles significantly improves cellular uptake and promotes deeper diffusion into skin tissues while minimizing systemic exposure. To further support topical administration, these vesicles were incorporated into a xanthan-based hydrogel, leading to enhanced formulation stability, sustained release of the active system, and increased skin permeability. This combined approach aims to maximize local bioavailability while maintaining a favorable safety profile.
Therapeutic evaluation in a murine model demonstrated a marked reduction in disease severity following treatment with these formulations. Both clinical assessment and histopathological analysis revealed outcomes comparable to those achieved with conventional corticosteroid therapy, suggesting a similar level of efficacy.
Altogether, these findings emphasize the potential of dendrimer-based delivery systems formulated in fluid vesicles and hydrogels as effective topical alternatives to standard corticosteroid treatments. This strategy offers a promising avenue for the development of innovative, locally acting therapies for psoriasis with reduced risk of systemic side effects.
